ArticleFrontiers in medicine2026
Precision targeting of gut-kidney axis: mucosal immunomodulation in IgA nephropathy-a perspective.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut-kidney axis in IgA nephropathy: mechanisms linking microbiota dysbiosis to immune dysregulation, Gd-IgA1 generation, and renal injury.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is a primary glomerular disease closely linked to mucosal immune dysregulation, involving a complex interplay between intestinal immune homeostasis and renal injury. The "gut-kidney axis" has recently emerged as a central conceptual framework for understanding IgAN pathogenesis, connecting intestinal mucosal immunity with kidney pathology. This perspective article scrutinizes the mechanistic role of this axis, focusing on key processes such as the production of galactose-deficient IgA1, intestinal barrier dysfunction, and gut microbiota dysbiosis. Building on this foundation, we propose "precision targeting of the gut-kidney axis" as a novel therapeutic paradigm for mucosal immunomodulation in IgAN, and discuss integrated strategies ranging from microbial and barrier modulation to specific immune interventions. By emphasizing multi-target, cross-organ approaches, this paradigm offers a promising alternative to conventional therapies and provides a translational roadmap for developing mechanism-based treatments in IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.